Patient-Based Therapeutics

AcuraStem is a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.

get to know us

Patient Focused

rp3.jpgrp1.jpgrp2.jpg

rp4.jpgThe main reason drugs fail in clinical trials is due to an over reliance on animal models, which leads to a poor understanding of the real human mechanisms driving disease. AcuraStem are leaders and inventors in the generation of individual patient models that accurately recapitulate neurodegenerative disease processes. This, what we call our patient-based approach, leads to more effective treatments, and treatments that can work broadly for patients, not limited to rare, genetically defined subtypes. 


learn about our work

Neurodegenerative Disease Areas

Latest News

December 5, 2022

Dr. Wen-Hsuan Chang, AcuraStem’s Head of Target Validation to present at the 33rd International Symposium on ALS/MND

Dr. Wen-Hsuan Chang, AcuraStem’s Head of Target Validation to present at the 33nd International Symposium on ALS/MND being held virtually on December 6-9, 2022. Dr. Chang will detail AcuraStem’s development program leveraging its best-in-class  iNeuroRx® platform, composed of patient-derived disease models that accurately recapitulate UNC13A pathology, to develop novel and potent UNC13A antisense oligonucleotide (ASO) drug candidates. UNC13A is one of the most significant genetic risk factors for ALS and FTD.

» Read more
November 4, 2022

Greater Los Angeles Walk to Defeat ALS on Nov 6, 2022

Team AcuraStem is honored to continue its partnership with Team Nanci and the ALS Association Golden West Chapter in the fight against ALS as a sponsor of the Greater Los Angeles Walk to Defeat ALS® on Sunday, November 6, at Exposition Park in Los Angeles.

» Read more
December 15, 2021

AcuraStem’s Development Candidate AS-202 Demonstrates Excellent Safety and Potency in Preclinical Models Representing Diverse Forms of ALS

AcuraStem (acurastem.com), a patient-based drug discovery platform company developing novel therapeutics for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases, announced the results of extensive preclinical studies on its lead program, AS-202, for ALS patients. The data were presented at the Motor Neuron Disease Association 32nd International Symposium on ALS/MND on December 9, by AcuraStem’s Head of Research, Wen-Hsuan Chang, Ph.D.

» Read more

Keep Up to Date with AcuraStem